• Addex Therapeutics regained full global rights to its GABAB positive allosteric modulator portfolio from Indivior on Sept. 25, 2026.
• Transaction returns a development candidate Indivior had selected, giving Addex full ownership and control of future development.
• Rights reversion followed Indivior’s R&D rationalization tied to the planned merger of its parent with Supernus Pharmaceuticals.
• Addex plans to weigh options, including new partnering discussions or further internal development of the substance use disorder candidate.
• Returned asset expands Addex’s GABAB PAM pipeline alongside its wholly owned chronic cough program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250100OMX_____CNEWS_EN_GNW1001274520_en) on September 25, 2026, and is solely responsible for the information contained therein.